MX2021007480A - Tratamiento de combinación para tumores sólidos utilizando docetaxel y un inhibidor de cyp3a. - Google Patents
Tratamiento de combinación para tumores sólidos utilizando docetaxel y un inhibidor de cyp3a.Info
- Publication number
- MX2021007480A MX2021007480A MX2021007480A MX2021007480A MX2021007480A MX 2021007480 A MX2021007480 A MX 2021007480A MX 2021007480 A MX2021007480 A MX 2021007480A MX 2021007480 A MX2021007480 A MX 2021007480A MX 2021007480 A MX2021007480 A MX 2021007480A
- Authority
- MX
- Mexico
- Prior art keywords
- docetaxel
- cyp3a inhibitor
- treatment
- solid tumors
- methods
- Prior art date
Links
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 title abstract 7
- 229960003668 docetaxel Drugs 0.000 title abstract 7
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 208000009011 Cytochrome P-450 CYP3A Inhibitors Diseases 0.000 title abstract 2
- 238000011284 combination treatment Methods 0.000 title 1
- 238000011282 treatment Methods 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229940123237 Taxane Drugs 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18215488 | 2018-12-21 | ||
| PCT/EP2019/086125 WO2020127607A1 (en) | 2018-12-21 | 2019-12-18 | Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021007480A true MX2021007480A (es) | 2021-10-13 |
Family
ID=64901398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021007480A MX2021007480A (es) | 2018-12-21 | 2019-12-18 | Tratamiento de combinación para tumores sólidos utilizando docetaxel y un inhibidor de cyp3a. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220071944A1 (enExample) |
| EP (1) | EP3897611A1 (enExample) |
| JP (3) | JP2022514960A (enExample) |
| KR (1) | KR20220004011A (enExample) |
| CN (1) | CN113473982A (enExample) |
| AU (2) | AU2019410062A1 (enExample) |
| BR (1) | BR112021012266A2 (enExample) |
| CA (1) | CA3124319C (enExample) |
| CL (1) | CL2021001635A1 (enExample) |
| IL (1) | IL284225A (enExample) |
| MX (1) | MX2021007480A (enExample) |
| PE (1) | PE20220129A1 (enExample) |
| WO (1) | WO2020127607A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3897610B1 (en) * | 2018-12-21 | 2025-04-16 | Modra Pharmaceuticals B.V. | Cancer treatment using docetaxel by controlling peak plasma levels |
| GB202201935D0 (en) | 2022-02-14 | 2022-03-30 | Modra Pharmaceuticals B V | Methods and compositions for treating cancer in taxane-resistant patients |
| CN116270617B (zh) * | 2023-03-29 | 2024-01-26 | 济宁医学院附属医院 | Arp2/3复合物抑制剂CK-666和多西他赛组合用于癌症治疗的制药用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101544498B1 (ko) | 2007-08-24 | 2015-08-17 | 스티칭 허트 네덜란드 칸커 인스티튜트 | 종양성 질환의 치료를 위한 조성물 |
| US9089544B2 (en) * | 2007-08-24 | 2015-07-28 | Slotervaart Participaties Bv | Composition |
| WO2010020799A2 (en) | 2008-08-22 | 2010-02-25 | Slotervaart Participaties Bv | Composition |
| GB0716591D0 (en) * | 2007-08-24 | 2007-10-03 | Vereniging Het Nl Kanker I | Composition |
| EP3897610B1 (en) * | 2018-12-21 | 2025-04-16 | Modra Pharmaceuticals B.V. | Cancer treatment using docetaxel by controlling peak plasma levels |
-
2019
- 2019-12-18 PE PE2021001053A patent/PE20220129A1/es unknown
- 2019-12-18 CN CN201980090621.4A patent/CN113473982A/zh active Pending
- 2019-12-18 KR KR1020217022969A patent/KR20220004011A/ko not_active Ceased
- 2019-12-18 AU AU2019410062A patent/AU2019410062A1/en not_active Abandoned
- 2019-12-18 BR BR112021012266-4A patent/BR112021012266A2/pt not_active Application Discontinuation
- 2019-12-18 EP EP19828725.2A patent/EP3897611A1/en active Pending
- 2019-12-18 CA CA3124319A patent/CA3124319C/en active Active
- 2019-12-18 MX MX2021007480A patent/MX2021007480A/es unknown
- 2019-12-18 JP JP2021536396A patent/JP2022514960A/ja active Pending
- 2019-12-18 US US17/416,946 patent/US20220071944A1/en active Pending
- 2019-12-18 WO PCT/EP2019/086125 patent/WO2020127607A1/en not_active Ceased
-
2021
- 2021-06-18 CL CL2021001635A patent/CL2021001635A1/es unknown
- 2021-06-20 IL IL284225A patent/IL284225A/en unknown
-
2023
- 2023-05-01 JP JP2023075514A patent/JP2023102786A/ja active Pending
- 2023-07-14 AU AU2023204693A patent/AU2023204693A1/en not_active Abandoned
-
2025
- 2025-03-24 JP JP2025049063A patent/JP2025094186A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PE20220129A1 (es) | 2022-01-27 |
| KR20220004011A (ko) | 2022-01-11 |
| CA3124319A1 (en) | 2020-06-25 |
| WO2020127607A1 (en) | 2020-06-25 |
| BR112021012266A2 (pt) | 2021-08-31 |
| IL284225A (en) | 2021-08-31 |
| AU2023204693A1 (en) | 2023-08-10 |
| JP2025094186A (ja) | 2025-06-24 |
| JP2022514960A (ja) | 2022-02-16 |
| JP2023102786A (ja) | 2023-07-25 |
| EP3897611A1 (en) | 2021-10-27 |
| AU2019410062A1 (en) | 2021-08-12 |
| US20220071944A1 (en) | 2022-03-10 |
| CN113473982A (zh) | 2021-10-01 |
| CA3124319C (en) | 2023-07-04 |
| CL2021001635A1 (es) | 2022-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4656246A3 (en) | Combination therapies for the treatment of cancer | |
| PE20191303A1 (es) | Compuestos con actividad antitumoral contra celulas cancerosas que tienen mutaciones en el exon 20 de egfr o her2 | |
| WO2018089669A3 (en) | Immunotherapeutic tumor treatment method | |
| WO2015184145A8 (en) | Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer | |
| MX2017007321A (es) | Terapias de combinacion. | |
| MX2019003938A (es) | Compuestos espirociclicos. | |
| MX2019014113A (es) | Terapia combinada para trastornos neuropsiquiatricos sensibles al antagonista de nmdar. | |
| PH12021551036A1 (en) | Anti-liv1 immune cell cancer therapy | |
| PH12021551047A1 (en) | Anti-ptk7 immune cell cancer therapy | |
| MY188911A (en) | Methods of treating bladder cancer | |
| PH12018501451A1 (en) | Formulations for treating bladder cancer | |
| WO2016160621A3 (en) | Nk-92 cells in combination therapy with cancer drugs | |
| EA201492187A1 (ru) | Способы лечения солидных опухолей с использованием кофермента q10 | |
| MX2023000549A (es) | Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr. | |
| WO2019143883A3 (en) | Compositions and methods for the treatment of cancer | |
| MX379622B (es) | Compuestos espirociclicos | |
| HK1250626A1 (zh) | 借助塞里班土单抗的组合治疗 | |
| MX2020001727A (es) | Terapia de combinacion. | |
| ZA202108677B (en) | Method of treating tumours | |
| MX2025008270A (es) | Uso prolongado de docetaxel en el tratamiento del cáncer. | |
| CL2021001635A1 (es) | Tratamiento combinado para tumores sólidos con docetaxel y un inhibidor de cyp3a | |
| PH12021553177A1 (en) | Pharmaceutical composition for treating tumor | |
| MX2016015568A (es) | Derivados de nucleosidos para el tratamiento del cancer. | |
| MX2021002818A (es) | Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k). | |
| PH12018502360A1 (en) | 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers |